CoChat

Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain

Open access
Scarlett, Jarrad M., Muta, Kenjiro, Brown, Jenny M., Rojas, Jennifer M., Matsen, Miles E., Acharya, Nikhil K., Secher, Anna, Ingvorsen, Camilla, Jorgensen, Rasmus, Høeg-Jensen, Thomas, Stefanovski, Darko, Bergman, Richard N., Piccinini, Francesca, Kaiyala, Karl J., Shiota, Masakazu, Morton, Gregory J., Schwartz, Michael W. · 2019 · Diabetes
Cited by 50

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

We recently reported that in rodent models of type 2 diabetes (T2D), a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces remission of hyperglycemia that is sustained for weeks. To clarify the peripheral mechanisms underlying this effect, we used the Zucker diabetic fatty fa/fa rat model of T2D, which, like human T2D, is characterized by progressive deterioration of pancreatic β-cell function after hyperglycemia onset. We report that although icv FGF1 injection delays the onset of β-cell dysfunction in these animals, it has no effect on either glucose-induced insulin secretion or insulin sensitivity. These observations suggest that FGF1 acts in the brain to stimulate insulin-independent glucose clearance. On the basis of our finding that icv FGF1 treatment increases hepatic glucokinase gene expression, we considered the possibility that increased hepatic glucose uptake (HGU) contributes to the insulin-independent glucose-lowering effect of icv FGF1. Consistent with this possibility, we report that icv FGF1 injection increases liver glucokinase activity by approximately twofold. We conclude that sustained remission of hyperglycemia induced by the central action of FGF1 involves both preservation of β-cell function and stimulation of HGU through increased hepatic glucokinase activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db18-0498

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 50

Metadata

Authors
Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N. K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., Stefanovski, D., Bergman, R. N., Piccinini, F., Kaiyala, K. J., Shiota, M., Morton, G. J., & Schwartz, M. W.
Venue
Diabetes
Published
2018-12-06
Volume
68
Issue
3
Pages
654-664
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2902206070
Cited by
50
References
16
FWCI
1.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain. https://app.cochat.ai/papers/10.2337/db18-0498
The paper
Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N. K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., Stefanovski, D., Bergman, R. N., Piccinini, F., Kaiyala, K. J., Shiota, M., Morton, G. J., & Schwartz, M. W. (2019). Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain. Diabetes. https://doi.org/10.2337/db18-0498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.